Viridian Therapeutics, Inc.

NasdaqCM:VRDN Stock Report

Market Cap: US$1.6b

Viridian Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Viridian Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-34.8%

Buyback Yield

Total Shareholder Yield-34.8%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate

Nov 14
We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Sep 11
Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Sep 10

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Jun 12

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

May 28
Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Sep 12
Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

May 15
Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Apr 18
Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Jan 08
Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Sep 09

Viridian Therapeutics board compensation committee approves inducement grants

Sep 02

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22
An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if VRDN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VRDN's dividend payments have been increasing.


Dividend Yield vs Market

Viridian Therapeutics Dividend Yield vs Market
How does VRDN dividend yield compare to the market?
SegmentDividend Yield
Company (VRDN)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.3%
Industry Average (Biotechs)2.3%
Analyst forecast (VRDN) (up to 3 years)0%

Notable Dividend: Unable to evaluate VRDN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VRDN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate VRDN's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VRDN has not reported any payouts.


Discover strong dividend paying companies